ブリナツモマブ (Japanese Wikipedia)
Analysis of information sources in references of the Wikipedia article "ブリナツモマブ" in Japanese language version.
refsWebsite
Global rank
Japanese rank
6,690th place
394th place
1,415th place
95th place
1st place
1st place
211th place
13th place
amgen.com
- "Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE Antibody Blinatumomab In Acute Lymphoblastic Leukemia" (Press release). Amgen. 1 July 2014.
- "Amgen's BiTE Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia" (Press release). Amgen. 9 October 2014.
doi.org
- “CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis”. Molecular Immunology 44 (8): 1935–43. (March 2007). doi:10.1016/j.molimm.2006.09.032. PMID 17083975.
- “FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease”. Clinical Cancer Research 25 (2): 473–477. (January 2019). doi:10.1158/1078-0432.CCR-18-2337. PMID 30254079.
drugs.com
- “Blinatumomab (Blincyto) Use During Pregnancy”. Drugs.com (29 May 2018). 14 March 2020閲覧。
fda.gov
fda.gov
- "FDA grants regular approval to blinatumomab and expands indication to include Philadelphia chromosome-positive B cell" (Press release). U.S. Food and Drug Administration (FDA). 12 July 2017. 2018年10月26日閲覧。
- Amgen (30 October 2012). Background Information for the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee Meeting 4 December 2012 (PDF). Blinatumomab (AMG 103) (Report). U.S. Food and Drug Administration (FDA). 2017年5月9日時点のオリジナル (PDF)よりアーカイブ。2019年12月16日閲覧。
accessdata.fda.gov
- “Drug Approval Package: Blincyto (blinatumomab) Injection NDA #125557”. U.S. Food and Drug Administration (FDA) (12 January 2015). 14 March 2020閲覧。
kegg.jp
- “KEGG DRUG: ブリナツモマブ”. www.kegg.jp. 2021年9月18日閲覧。
nih.gov
pubmed.ncbi.nlm.nih.gov
- “CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis”. Molecular Immunology 44 (8): 1935–43. (March 2007). doi:10.1016/j.molimm.2006.09.032. PMID 17083975.
- “FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease”. Clinical Cancer Research 25 (2): 473–477. (January 2019). doi:10.1158/1078-0432.CCR-18-2337. PMID 30254079.
dailymed.nlm.nih.gov
- “Blincyto- blinatumomab kit”. DailyMed (19 April 2019). 14 March 2020閲覧。
nikkei.com
- “アステラス製薬など、ブリナツモマブを日本で再発又は難治性のB細胞性急性リンパ性白血病の治療薬として製造販売承認申請”. 日本経済新聞 (2018年1月9日). 2021年9月18日閲覧。
nikkeibp.co.jp
medical.nikkeibp.co.jp
- がんナビ. “BiTE抗体ブリナツモマブが再発または難治性のB細胞性急性リンパ性白血病を対象に承認”. がんナビ. 2021年9月18日閲覧。
pmda.go.jp
info.pmda.go.jp
- “ビーリンサイト点滴静注用35μg 添付文書”. www.info.pmda.go.jp. 2021年9月18日閲覧。
- “ビーリンサイト点滴静注用35μg インタビューフォーム”. www.info.pmda.go.jp. 2021年9月18日閲覧。
web.archive.org
- Amgen (30 October 2012). Background Information for the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee Meeting 4 December 2012 (PDF). Blinatumomab (AMG 103) (Report). U.S. Food and Drug Administration (FDA). 2017年5月9日時点のオリジナル (PDF)よりアーカイブ。2019年12月16日閲覧。